Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23900009 | 0.82 | MAPT (0.47) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL30083748 | 0.80 | TAAR1 (0.44) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL1042615 | 0.80 | TAAR1 (0.44) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL21979047 | 0.78 | NPC1 (0.41) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL25204018 | 0.78 | ERN1 (0.38) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL17028317 | 0.78 | MAPT (0.44) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL30905948 | 0.78 | NPC1 (0.41) | MAPTNPSR1L3MBTL1POLBALDH1A1 | |
| SCHEMBL23272901 | 0.78 | MAPK14 (0.31) | — | |
| SCHEMBL29823297 | 0.78 | MAPK14 (0.31) | — | |
| SCHEMBL10086105 | 0.76 | TUBB1 (0.42) | MAPTNFE2L2LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025021193-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2025020191-A1 | STEROID COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
| WO-2017100546-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7038047-B2 | Substituted 6-(2-methoxyphenyl) triazolopyrimides as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2006-05-02 | — | — | US | disclosed |
| US-20040167136-A1 | Substituted 6-(2-methoxyphenyl) triazolopyrimides as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-26 | — | — | US | disclosed |
| EP-1412356-A1 | SUBSTITUTED 6-(2-METHOXYPHENYL)TRIAZOLOPYRIMIDINES AS FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008416-A1 | SUBSTITUTED 6-(2-METHOXYPHENYL) TRIAZOLOPYRIMIDES AS FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | MAPT 2447/4885NPSR1 4340/4885L3MBTL1 2796/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | MAPT 2447/4885NPSR1 4340/4885L3MBTL1 2796/4885 |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 | MAPT 30/4885NPSR1 1492/4885L3MBTL1 2628/4885 |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | MAPT 1099/4885NPSR1 186/4885L3MBTL1 3942/4885 |
| US-20040167136-A1 | Substituted 6-(2-methoxyphenyl) triazolopyrimides as fungicides | CBR3, CBR1, CNPY2 | MAPT 4181/4885NPSR1 2929/4885L3MBTL1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.